|
127 Companies |
|
139 Products |
|
139 Products |
|
89 Mechanisms of Action |
|
9 Trials |
|
1220 News |
|
| «12...13141516171819202122232425» |
- 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., erlotinib / Generic mfg.
New P1 trial, Surgery, Metastases: Oxaliplatin, Fluorouracil, Erlotinib Hydrochloride, and Radiation Therapy Before Surgery and Erlotinib Hydrochloride After Surgery in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction (clinicaltrials.gov) - Mar 20, 2012
P1, N=64, Active, not recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
- | Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Enrollment closed: Randomized Controlled Study of Postoperative Adjuvant Therapy for Gastric Cancer Using TS-1 or TS-1+PSK (clinicaltrials.gov) - Mar 19, 2012
P3, N=280, Active, not recruiting, Sponsor: Hokuriku-Kinki Immunochemotherapy Study Group
Recruiting --> Active, not recruiting
- New P2 trial: Evaluation of Diagnostic Methods and Dietary Treatment of Diabetic Gastroparesis (clinicaltrials.gov) - Mar 15, 2012
P2, N=50, Recruiting, Sponsor: G
- carboplatin / Generic mfg., capecitabine / Generic mfg., epirubicin / Generic mfg.
Trial completion, Metastases: Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor (clinicaltrials.gov) - Mar 6, 2012
P1/2, N=0, Completed, Sponsor: National Institutes of Health Clinical Center (CC)
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Enrollment change: Acceptability of Less Harmful Alternatives to Cigarettes (clinicaltrials.gov) - Mar 4, 2012
P=N/A, N=67, Completed, Sponsor: Roswell Park Cancer Institute
Active, not recruiting --> Completed N=100 --> 67
- Trial completion: Acceptability of Less Harmful Alternatives to Cigarettes (clinicaltrials.gov) - Mar 4, 2012
P=N/A, N=67, Completed, Sponsor: Roswell Park Cancer Institute
N=100 --> 67 Active, not recruiting --> Completed
- Trial completion, Metastases: High-Dose Chemotherapy in Treating Patients With Advanced Stomach Cancer (clinicaltrials.gov) - Mar 1, 2012
P2, N=135, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
Trial completion, Metastases: Study of PEP02, Irinotecan or Docetaxel in Gastric or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov) - Feb 29, 2012
P2, N=135, Completed, Sponsor: PharmaEngine
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap
Trial termination: CRUK-PH1/105: Treated Blood Cells, Cyclophosphamide, Fludarabine Phosphate, and Aldesleukin in Treating Patients With Cancer (clinicaltrials.gov) - Feb 26, 2012
P1, N=14, Terminated, Sponsor: Cancer Research UK
Active, not recruiting --> Completed Recruiting --> Terminated; due to safety concerns and lack of efficacy
- Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap
Enrollment change: CRUK-PH1/105: Treated Blood Cells, Cyclophosphamide, Fludarabine Phosphate, and Aldesleukin in Treating Patients With Cancer (clinicaltrials.gov) - Feb 26, 2012
P1, N=14, Terminated, Sponsor: Cancer Research UK
Recruiting --> Terminated; due to safety concerns and lack of efficacy N=22 --> 14
- Enrollment change: CRUK-PH1-101: Vaccine Therapy in Treating Patients With Epstein-Barr Virus-Related Cancer (clinicaltrials.gov) - Feb 26, 2012
P1, N=16, Completed, Sponsor: Cancer Research UK
N=22 --> 14 N=22 --> 16
- Trial completion: CRUK-PH1-101: Vaccine Therapy in Treating Patients With Epstein-Barr Virus-Related Cancer (clinicaltrials.gov) - Feb 26, 2012
P1, N=16, Completed, Sponsor: Cancer Research UK
N=22 --> 16 Active, not recruiting --> Completed
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., floxuridine / Generic mfg.
Trial completion, Metastases: Adjuvant Intraperitoneal Floxuridine Added to Chemoradiation for Fully Resected Advanced Stomach Cancer (clinicaltrials.gov) - Feb 26, 2012
P2, N=28, Completed, Sponsor: New York University School of Medicine
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Inlyta (axitinib) / Pfizer
Enrollment change, Combination therapy, Metastases: Study Of Axitinib In Combination With Cisplatin And Capecitabine In Patients With Advanced Gastric Cancer (clinicaltrials.gov) - Feb 22, 2012
P1, N=22, Completed, Sponsor: Pfizer
Active, not recruiting --> Completed N=30 --> 22
- sunitinib / Generic mfg.
Enrollment closed, Metastases: Sunitinib, Irinotecan, Fluorouracil, and Leucovorin In Treating Patients With Advanced Stomach Cancer or Gastroesophageal Cancer (clinicaltrials.gov) - Feb 21, 2012
P1, N=30, Active, not recruiting, Sponsor: Roswell Park Cancer Institute
N=30 --> 22 Recruiting --> Active, not recruiting
- | Enrollment open, Metastases: Efficacy of Laparoscopic Subtotal Gastrectomy With D2 Lymph Node Dissection for Locally Advanced Gastric Cancer (clinicaltrials.gov) - Feb 19, 2012
P3, N=1050, Recruiting, Sponsor: Ajou University School of Medicine
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- || New P3 trial, Surgery, Biopsy: Quality Control Study of Laparoscopic Sentinel Node Biopsy in Early Gastric Cancer (clinicaltrials.gov) - Feb 15, 2012
P3, N=160, Recruiting, Sponsor: National Cancer Center, Korea
- Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
New P2 trial, Metastases: The Efficacy of Oxaliplatin Plus S-1 for Treatment of Gastric Cancer (clinicaltrials.gov) - Feb 9, 2012
P2, N=44, Recruiting, Sponsor: Chinese Academy of Medical Sciences
- ||||||| aspirin/omeprazole / Generic mfg., aspirin / Generic mfg.
Trial completion: A Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers (clinicaltrials.gov) - Feb 9, 2012
P3, N=530, Completed, Sponsor: POZEN
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||||||| aspirin/omeprazole / Generic mfg., aspirin / Generic mfg.
Trial completion: Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers (clinicaltrials.gov) - Feb 9, 2012
P3, N=519, Completed, Sponsor: POZEN
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | telatinib (BAY 57- 9352) / EddingPharm
Enrollment change, Combination therapy, Metastases: A Study of Telatinib in Combination With Chemotherapy in Subjects With Advanced Gastric Cancer (clinicaltrials.gov) - Feb 6, 2012
P2, N=48, Completed, Sponsor: ACT Biotech, Inc
Active, not recruiting --> Completed N=35 --> 48
- Farydak (panobinostat) / Secura Bio
New P2 trial, Epigenetic controller, Metastases: Histone Deacetylases - Gastric Cancer (HDAC-GaCa-2008) (clinicaltrials.gov) - Feb 6, 2012
P2, N=28, Terminated, Sponsor: Technische Universit
- | telatinib (BAY 57- 9352) / EddingPharm
Trial completion, Combination therapy, Metastases: A Study of Telatinib in Combination With Chemotherapy in Subjects With Advanced Gastric Cancer (clinicaltrials.gov) - Feb 6, 2012
P2, N=48, Completed, Sponsor: ACT Biotech, Inc
N=35 --> 48 Active, not recruiting --> Completed
- cisplatin / Generic mfg., capecitabine / Generic mfg., docetaxel / Generic mfg.
New P1/2 trial, Metastases: XPID: Safety Study of Combined Systemic and Intraperitoneal Chemotherapy to Treat Stomach Cancer (clinicaltrials.gov) - Feb 1, 2012
P1/2, N=37, Recruiting, Sponsor: Asan Medical Center
- | irinotecan / Generic mfg., docetaxel / Generic mfg.
Enrollment closed, Metastases: Study of Irinotecan and Docetaxel in Patients With Metastatic or Unresectable Gastric or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov) - Jan 31, 2012
P2, N=40, Active, not recruiting, Sponsor: University of Southern California
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- gene-modified anti-CEA T cells / Sorrento
Enrollment change: Trial of 2nd Generation Anti-CEA Designer T Cells in Gastric Cancer (clinicaltrials.gov) - Jan 30, 2012
P1, N=0, Withdrawn, Sponsor: Roger Williams Medical Center
Recruiting --> Active, not recruiting N=26 --> 0
- sirolimus / Generic mfg.
New P1 trial: Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors (clinicaltrials.gov) - Jan 30, 2012
P1, N=30, Recruiting, Sponsor: Roswell Park Cancer Institute
- || New P3 trial: Antibiotic Prophylaxis in the Prevention of Surgical Site Infections After Selected Urgent Abdominal Surgical Procedures (clinicaltrials.gov) - Jan 29, 2012
P3, N=187, Completed, Sponsor: The Faculty Hospital Na Bulovce
- | Erbitux (cetuximab) / Eli Lilly
Enrollment closed, Combination therapy, Metastases: EMR 062202-058: Cetuximab in Combination With S-1 and Cisplatin in Gastric Cancer (clinicaltrials.gov) - Jan 24, 2012
P2, N=40, Active, not recruiting, Sponsor: Merck KGaA
N=26 --> 0 Recruiting --> Active, not recruiting
- cisplatin / Generic mfg., capecitabine / Generic mfg., docetaxel / Generic mfg.
New P2 trial, Surgery: DoCCS: A Multicenter Phase II Study of Neoadjuvant Docetaxel, Cisplatin and Capecitabine and Protocolized Surgery in Resectable Gastric Cancer (clinicaltrials.gov) - Jan 23, 2012
P2, N=50, Completed, Sponsor: Jeroen Bosch Ziekenhuis
- | carboplatin / Generic mfg., everolimus / Generic mfg., paclitaxel / Generic mfg.
New P1/2 trial, Metastases: Gastric Cancer RAD001 Study (clinicaltrials.gov) - Jan 18, 2012
P1/2, N=53, Recruiting, Sponsor: Chinese University of Hong Kong
- | irinotecan / Generic mfg., docetaxel / Generic mfg.
Trial completion, Metastases: Second-line Therapy Versus Supportive Care for Pretreated Advanced Gastric Cancer (clinicaltrials.gov) - Jan 18, 2012
P3, N=200, Completed, Sponsor: Samsung Medical Center
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||||| Herceptin (trastuzumab) / Roche
Enrollment open: A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer (clinicaltrials.gov) - Jan 16, 2012
P3, N=400, Recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Avastin (bevacizumab) / Roche
Trial completion, Metastases: Study of Docetaxel, Cisplatin, and Fluorouracil (Modified DCF) With Bevacizumab in Patients With Unresectable or Metastatic Gastroesophageal Adenocarcinoma (clinicaltrials.gov) - Jan 16, 2012
P2, N=46, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- |||||||||| AiTan (rivoceranib) / HLB Bio Group
New P3 trial, Metastases: Phase III Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer (clinicaltrials.gov) - Jan 12, 2012
P3, N=270, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | cisplatin / Generic mfg., gefitinib / Generic mfg., irinotecan / Generic mfg.
Enrollment change, Metastases: Cisplatin and Irinotecan Chemotherapy, Followed by ZD 1839 (Iressa) in Patients With Esophageal or Gastric Carcinomas (clinicaltrials.gov) - Jan 11, 2012
P2, N=21, Completed, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Active, not recruiting --> Completed N=40 --> 21
- | Voquezna (vonoprazan) / Takeda, Phathom Pharma
Enrollment open: Long-term Extension Study of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Non-steroidal Anti-inflammatory Drug (NSAID) (clinicaltrials.gov) - Jan 11, 2012
P3, N=420, Recruiting, Sponsor: Takeda Pharmaceutical Company Limited
N=40 --> 21 Not yet recruiting --> Recruiting
- |||||| Voquezna (vonoprazan) / Takeda, Phathom Pharma
Enrollment open: Long-term Extension Study of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Low-dose Aspirin (clinicaltrials.gov) - Jan 11, 2012
P3, N=450, Recruiting, Sponsor: Takeda
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | cisplatin / Generic mfg., gefitinib / Generic mfg., irinotecan / Generic mfg.
Trial completion, Metastases: Cisplatin and Irinotecan Chemotherapy, Followed by ZD 1839 (Iressa) in Patients With Esophageal or Gastric Carcinomas (clinicaltrials.gov) - Jan 11, 2012
P2, N=21, Completed, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Not yet recruiting --> Recruiting Terminated --> Completed
- || New P3 trial: Helicobacter Pylori Eradication After Endoscopic Resection of Gastric Tumors (clinicaltrials.gov) - Jan 10, 2012
P3, N=855, Completed, Sponsor: Seoul National University Hospital
- |||| 5-fluorouracil / Generic mfg., albumin-bound paclitaxel / Generic mfg.
Trial completion: Phase II Study of ABI-007 for Gastric Cancer (clinicaltrials.gov) - Jan 10, 2012
P2, N=56, Completed, Sponsor: Taiho Pharmaceutical Co., Ltd.
Terminated --> Completed Active, not recruiting --> Completed
- | Trial completion: Phase III Trial of DP Followed by FOLFIRI or the Reverse Sequence in Unresectable Gastric Cancer (clinicaltrials.gov) - Jan 10, 2012
P3, N=200, Completed, Sponsor: Samsung Medical Center
Active, not recruiting --> Completed Terminated --> Completed
- Avastin (bevacizumab) / Roche
Enrollment closed, Metastases: Pre-operative Chemotherapy Plus Bevacizumab With Early Salvage Therapy Based on PET Assessment of Response in Patients With Locally Advanced But Resectable Gastric and GEJ Adenocarcinoma (clinicaltrials.gov) - Jan 4, 2012
P2, N=60, Active, not recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Terminated --> Completed Recruiting --> Active, not recruiting
- | Herceptin (trastuzumab) / Roche
New P2 trial: HerXO: Efficacy and Safety of Trastuzumab, Capecitabine y Oxaliplatine as Treatment Gastric Cancer Metastatic (HER2)Positive (clinicaltrials.gov) - Jan 2, 2012
P2, N=51, Active, not recruiting, Sponsor: Fundaci
- Trial completion: Confocal Laser Endomicroscopy for in Vivo Molecular Imaging of Gastric Cancer by Targeting MG7-Ag (clinicaltrials.gov) - Dec 28, 2011
P=N/A, N=5, Completed, Sponsor: Shandong University
Recruiting --> Active, not recruiting Recruiting --> Completed
- ||| Trial completion: PUB: China Survey of Peptic Ulcer Bleeding (clinicaltrials.gov) - Dec 28, 2011
P=N/A, N=1044, Completed, Sponsor: AstraZeneca
Recruiting --> Completed Active, not recruiting --> Completed
- | montelukast / Generic mfg.
Trial completion: Montelukast in the Treatment of Duodenal Eosinophilia (clinicaltrials.gov) - Dec 27, 2011
P=N/A, N=24, Completed, Sponsor: Children's Mercy Hospital Kansas City
Active, not recruiting --> Completed Recruiting --> Completed
- | pazopanib / Generic mfg.
New P2 trial, Metastases: PaFLO: FLO +/- Pazopanib as First-line Treatment in Advanced Gastric Cancer (clinicaltrials.gov) - Dec 21, 2011
P2, N=75, Recruiting, Sponsor: Charite University, Berlin, Germany
- | cabazitaxel / Generic mfg.
New P1 trial, Metastases: GASTANA: Cabazitaxel in Asian Patients With Advanced Gastric Cancer Who Failed Prior Chemotherapy (clinicaltrials.gov) - Dec 21, 2011
P1, N=16, Completed, Sponsor: Sanofi
- New P3 trial, HEOR: Impact of Roux-En-Y Pouch Reconstruction Compared With Conventional Roux-En-Y Reconstruction on Health-Related Quality of Life in Patients Undergoing Total Gastrectomy for Adenocarcinoma (clinicaltrials.gov) - Dec 12, 2011
P3, N=12, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center